Clinical Trials Logo

Compulsive Behavior clinical trials

View clinical trials related to Compulsive Behavior.

Filter by:

NCT ID: NCT00264238 Completed - Clinical trials for Obsessive-Compulsive Disorder

Memantine Augmentation in Obsessive-Compulsive Disorder

Start date: January 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

NCT ID: NCT00257361 Withdrawn - Clinical trials for Obsessive Compulsive Disorder

D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder

Start date: July 2005
Phase: Phase 2
Study type: Interventional

We propose to undertake an initial study of DCS to determine whether it has any short-term clinical benefits when added to standard ERP therapy in adults with OCD.

NCT ID: NCT00254735 Completed - Clinical trials for Obsessive Compulsive Disorder

Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

Start date: April 2002
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

NCT ID: NCT00251303 Completed - Clinical trials for Autism Spectrum Disorder

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.

NCT ID: NCT00234689 Completed - Clinical trials for Obsessive Compulsive Disorder

Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

Start date: January 2002
Phase: N/A
Study type: Interventional

Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD

NCT ID: NCT00229385 Completed - Schizophrenia Clinical Trials

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Start date: January 2006
Phase: N/A
Study type: Interventional

Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

NCT ID: NCT00229320 Completed - Clinical trials for Obsessive Compulsive Disorder

Short Term Group Therapy for OCD

Start date: February 2005
Phase: N/A
Study type: Interventional

Assessing OCD before and after group therapy

NCT ID: NCT00215137 Completed - OCD Clinical Trials

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms.

NCT ID: NCT00211822 Terminated - Clinical trials for Obsessive Compulsive Disorder

Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)

Start date: November 2004
Phase: N/A
Study type: Observational

This study will explore the brain processes associated with inhibition and reward processing in pathological gamblers and people with obsessive compulsive disorder compared to healthy controls.

NCT ID: NCT00187928 Completed - Clinical trials for Obsessive-Compulsive Disorder

Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD). Topiramate is an investigational drug for OCD, which means it has not been approved by the U.S. Food and Drug Administration (FDA). Topiramate has been approved as an add-on therapy for adults and children with partial onset seizures or generalized tonic-clonic seizures, and for patients 2 years of age and older with a severe form of epilepsy called Lennox-Gastaut Syndrome. Up to 96 subjects will be enrolled in this study. This study consists of three phases: Washout/Screening Phase, Double-Blind Phase, and Taper Phase. The total expected length of your participation in the study is approximately four months.